Literature DB >> 11216654

Combined modification of intracellular and extracellular loci on human gonadotropin-releasing hormone receptor provides a mechanism for enhanced expression.

G Maya-Núñez1, J A Janovick, P M Conn.   

Abstract

The mammalian gonadotropin-releasing hormone (GnRH) receptor (GnRH-R) has been a therapeutic target for human and animal medicine. This receptor is a unique G-protein-coupled receptor that lacks the intracellular C-terminal domain commonly associated with this family. Development of highthrough put screens for agents active in humans has been hampered by low expression levels of the hGnRH-R in cellular models. Two sites have attracted the interest of laboratories studying regulation of expression. The chimeric addition of the C-terminal tail from catfish GnRH-R (cfGnRH-R) to the rat GnRH-R significantly augmented receptor expression in GH3 cells. In addition, rodent GnRH-R contains 327 amino acids, but cow, sheep, and human GnRH-R (hGnRH-R) contain 328 residues, the "additional" residue being a Lys 191. Deletion of Lys 191 (del 191) from the hGnRH-R resulted in increased receptor expression levels and decreased internalization rates in both COS-7 and HEK 293 cells. In this study, the combined effect of the addition of the C-tail from cfGnRH-R and deletion of the Lys 191 from the hGnRH-R was compared to expression of the wild-type (WT) or either alteration alone in a transient expression system using primate cells. The altered receptor (hGnRH-R[del 191]-C-tail) showed significantly increased receptor expression at the cell surface compared with the WT or either modification alone. The inositol phosphate response to stimulation was also significantly elevated in response to GnRH agonist. After treatment with a GnRH agonist, the altered receptors showed a slower internalization rate. The homologous steady-state regulation of the WT and the altered receptors was similar, although the response of the altered receptors was significantly decreased. These results suggest that the conformational change in the receptor as a result of the deletion of Lys 191 and the addition of the C-terminus tail substantially increased the steady-state receptor expression and decreased internalization and homologous regulation. Because the effects on expression are greater than additive, it appears that these alterations exert their effects by differing means. These techniques for expression of the hGnRH-R in transfected mammalian cells provide the basis for a therapeutic screen for GnRH analogs, agonists, and antagonists of the hGnRH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216654     DOI: 10.1385/ENDO:13:3:401

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  23 in total

1.  Contrasting internalization kinetics of human and chicken gonadotropin-releasing hormone receptors mediated by C-terminal tail.

Authors:  A J Pawson; A Katz; Y M Sun; J Lopes; N Illing; R P Millar; J S Davidson
Journal:  J Endocrinol       Date:  1998-03       Impact factor: 4.286

Review 2.  Gonadotropin-releasing hormone receptors: structure and signal transduction pathways.

Authors:  S S Stojilkovic; J Reinhart; K J Catt
Journal:  Endocr Rev       Date:  1994-08       Impact factor: 19.871

3.  The calcium requirement in GnRH-stimulated LH release is not mediated through a specific action on receptor binding.

Authors:  J Marian; P M Conn
Journal:  Life Sci       Date:  1980-07-07       Impact factor: 5.037

Review 4.  Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor.

Authors:  S C Sealfon; H Weinstein; R P Millar
Journal:  Endocr Rev       Date:  1997-04       Impact factor: 19.871

5.  Use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover.

Authors:  W R Huckle; P M Conn
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Isolation and characterisation of the marmoset gonadotrophin releasing hormone receptor: Ser(140) of the DRS motif is substituted by Phe.

Authors:  B Byrne; A McGregor; P L Taylor; R Sellar; F E Rodger; H M Fraser; K A Eidne
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

Review 7.  Regulation of transmembrane signaling by receptor phosphorylation.

Authors:  D R Sibley; J L Benovic; M G Caron; R J Lefkowitz
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582

8.  Simultaneous and independent visualization of the gonadotropin-releasing hormone receptor and its ligand: evidence for independent processing and recycling in living cells.

Authors:  A Cornea; J A Janovick; X Lin; P M Conn
Journal:  Endocrinology       Date:  1999-09       Impact factor: 4.736

9.  Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor.

Authors:  B F O'Dowd; M Hnatowich; M G Caron; R J Lefkowitz; M Bouvier
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

10.  Identification of a cytoplasmic Ser-Thr-Leu motif that determines agonist-induced internalization of the AT1 angiotensin receptor.

Authors:  L Hunyady; M Bor; T Balla; K J Catt
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

View more
  12 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism.

Authors:  Guadalupe Maya-Núñez; Jo Ann Janovick; Arturo Aguilar-Rojas; Eduardo Jardón-Valadez; Alfredo Leaños-Miranda; Teresa Zariñan; Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2011-01-26       Impact factor: 4.102

Review 3.  Regulation of G protein-coupled receptor export trafficking.

Authors:  Chunmin Dong; Catalin M Filipeanu; Matthew T Duvernay; Guangyu Wu
Journal:  Biochim Biophys Acta       Date:  2006-09-23

4.  Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor.

Authors:  Rodrigo Ayala Yáñez; P Michael Conn
Journal:  Cell Biochem Funct       Date:  2010-01       Impact factor: 3.685

5.  Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.

Authors:  Teresa Zariñán; Marco A Perez-Solís; Guadalupe Maya-Núñez; Patricia Casas-González; P Michael Conn; James A Dias; Alfredo Ulloa-Aguirre
Journal:  Mol Cell Endocrinol       Date:  2010-03-04       Impact factor: 4.102

Review 6.  Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Adv Pharmacol       Date:  2011

7.  The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane.

Authors:  Michelle Re; Macarena Pampillo; Martin Savard; Céléna Dubuc; Craig A McArdle; Robert P Millar; P Michael Conn; Fernand Gobeil; Moshmi Bhattacharya; Andy V Babwah
Journal:  PLoS One       Date:  2010-07-08       Impact factor: 3.240

8.  Species sequence differences determine the interaction of GnRH receptor with the cellular quality control system.

Authors:  Alejandro Cabrera-Wrooman; Jo Ann Janovick; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-07-24       Impact factor: 4.102

9.  Evolved regulation of gonadotropin-releasing hormone receptor cell surface expression.

Authors:  Jo Ann Janovick; Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

10.  Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231.

Authors:  Arturo Aguilar-Rojas; Maira Huerta-Reyes; Guadalupe Maya-Núñez; Fabián Arechavaleta-Velásco; P Michael Conn; Alfredo Ulloa-Aguirre; Jesús Valdés
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.